Objective: To explore the clinical efficacy of different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension. Methods: A total of 60 neonates with persistent pulmonary hypertension were...Objective: To explore the clinical efficacy of different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension. Methods: A total of 60 neonates with persistent pulmonary hypertension were diagnosed and treated in this hospital between August 2013 and April 2017, all of them received vardenafil therapy and they were divided into low dose group (2.5 mg), medium dose group (5 mg) and high dose group (10 mg) according to the doses, 20 cases in each group. The differences in pulmonary arterial systolic pressure (PASP) levels as well as the contents of myocardial injury markers and endothelial injury indexes were compared among the three groups of children after 1 month of treatment. Results: After 1 month of treatment, the PASP level in high dose group was lower than that in medium dose group and low dose group;myocardial injury markers hs-cTnT, BNP and LDH contents in peripheral blood were lower than those of medium dose group and low dose group;endothelial injury indexes ET-1 and HIF-1 contents in peripheral blood were lower than those of medium dose group and low dose group whereas ADM and NO contents were higher than those of medium dose group and low dose group. The change trend of the above indicators in medium dose group was greater than that in low dose group. Conclusion: Vardenafil is a reliable drug for clinical treatment of neonatal persistent pulmonary hypertension, and the efficacy is dose-dependent.展开更多
文摘Objective: To explore the clinical efficacy of different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension. Methods: A total of 60 neonates with persistent pulmonary hypertension were diagnosed and treated in this hospital between August 2013 and April 2017, all of them received vardenafil therapy and they were divided into low dose group (2.5 mg), medium dose group (5 mg) and high dose group (10 mg) according to the doses, 20 cases in each group. The differences in pulmonary arterial systolic pressure (PASP) levels as well as the contents of myocardial injury markers and endothelial injury indexes were compared among the three groups of children after 1 month of treatment. Results: After 1 month of treatment, the PASP level in high dose group was lower than that in medium dose group and low dose group;myocardial injury markers hs-cTnT, BNP and LDH contents in peripheral blood were lower than those of medium dose group and low dose group;endothelial injury indexes ET-1 and HIF-1 contents in peripheral blood were lower than those of medium dose group and low dose group whereas ADM and NO contents were higher than those of medium dose group and low dose group. The change trend of the above indicators in medium dose group was greater than that in low dose group. Conclusion: Vardenafil is a reliable drug for clinical treatment of neonatal persistent pulmonary hypertension, and the efficacy is dose-dependent.
